However, response rates varied significantly between PTCL subtypes, with the best response documented in patients with ENKTL (63.2%, 12/19), compared to ALK+ALCL (53.8%, 7/13), ALK-negative ALCL (42.9%, 3/7), and PTCL-NOS (17.9%, 5/28) [69]. Here, ALK is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.